Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 20;227:108727. doi: 10.1016/j.clim.2021.108727

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Published by Elsevier Inc.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 5 — The anti-COVID-19 clinical therapies of NK cells.

The natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded (CYNK-001) are in clinical test to determine the safety and efficacy in patients with moderate coronavirus disease 2019(COVID-19) disease (NCT04365101). NK cells derived from human umbilical cord blood expressing NKG2D-ACE2 chimeric antigen receptors(CARs) and culture-expanded are in clinical test in early-stage COVID-19 patients (within 14 days of illness) (NCT04324996).